Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry
Clinical & Experimental Ophthalmology · 2025
DOI: 10.1111/ceo.70033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Trung M Dang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eye Clinic Albury Wodonga, Albury, New South Wales, Australia. Hauptthemen laut MEDLINE: Registries, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Wet Macular Degeneration. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Background
We analysed 12‐month real‐world outcomes of treatment of eyes with neovascular age‐related macular degeneration switched to brolucizumab from a first‐generation VEGF inhibitor to determine whether switching chronically active eyes that required frequent treatment improved control of the disease safely with fewer injections.
Methods
Retrospective analysis of Australian and Italian data from the prospectively designed observational Fight Retinal Blindness! registry. We studied eyes that switched to brolucizumab and received at least two injections with 12 months of follow‐up.
Results
Of the 81 eligible eyes, the proportion of inactive lesions increased from 5% at baseline to 37% 12 months after switching to brolucizumab ( p < 0.001). Mean (95% CI) visual acuity (VA) was stable (0.6 [−1.5, 2.8] letters, p = 0.55), while median treatment intervals increased from 44 to 63 days ( p < 0.001). Nearly a third (30%) of eyes switched back to another VEGF inhibitor within 12 months. Eyes that stayed on brolucizumab had a significantly longer mean treatment interval at 12 months than eyes that switched off it (66.1 [Q1, Q3: 56, 91] vs. 49 [28, 63.2] days, p ≤ 0.001) while VA change and inactivation rates were similar. Intraocular inflammation (IOI) was recorded in 7 (9%) eyes receiving at least one injection of brolucizumab.
Conclusions
Eyes that switched from a first generation VEGF inhibitor to brolucizumab in routine clinical practice achieved a clinically significant extension of their treatment interval, with more than a third becoming inactive but with a relatively high rate of IOI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Clinic Albury Wodonga, Albury, New South Wales, Australia.
- The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, Sydney, New South Wales, Australia.
- Eye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco Hospital, University of Milan, Milan, Italy.
- Marsden Eye Specialists, Sydney, New South Wales, Australia.
- Strathfield Retina Clinic, Sydney, New South Wales, Australia.
- Department of Ophthalmology, Royal Free London NHS Foundation Trust, London, UK.
ORCID-Profile: Francesco Romano, Mariano Cozzi
Förderung
- Novartis
Zitieren
APA
Dang, T. M., Invernizzi, A., Nguyen, V., Hashimoto, Y., Romano, F., Cozzi, M., Arnold, J., Wong, J., Mehta, H., Fraser-Bell, S., Barry, R., Barthelmes, D., Gillies, M., & Luckie, A. (2025). Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70033
Vancouver
Dang TM, Invernizzi A, Nguyen V, Hashimoto Y, Romano F, Cozzi M, et al. Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.70033
BibTeX
@article{Dang2025,
author = {Dang, Trung M and Invernizzi, Alessandro and Nguyen, Vuong and Hashimoto, Yohei and Romano, Francesco and Cozzi, Mariano and Arnold, Jennifer and Wong, James and Mehta, Hemal and Fraser-Bell, Samantha and Barry, Richard and Barthelmes, Daniel and Gillies, Mark and Luckie, Alan},
title = {Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
doi = {10.1111/ceo.70033}
}
EUVIMED